Table 2.
Univariate and multivariate Cox hazard analysis of potential factors associated with progression‐free survival
| Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|
| Category | PFS (months) | HR | 95% CI | P‐value | HR | 95% CI | P‐value |
| Age, years | |||||||
| <75 vs. ≥75 | 6.7 vs. 6.3 | 1.27 | 0.85–1.89 | 0.246 | |||
| ECOG performance status | |||||||
| 0–1 vs. 2–3 | 7.2 vs. 4.1 | 1.61 | 1.29–2.00 | <0.001 | 1.52 | 1.20–1.93 | 0.001 |
| Smoking history never vs. current plus former | 8.7 vs. 6.5 | 2.32 | 1.08–5.00 | 0.026 | 2.46 | 1.13–5.36 | 0.024 |
| Interstitial pneumonia without vs. with | 6.7 vs. 6.5 | 1.58 | 1.01–2.46 | 0.047 | 1.72 | 1.08–2.72 | 0.022 |
| Stage | |||||||
| LD vs. ED | 8.9 vs. 5.4 | 2.88 | 1.94–4.27 | <0.001 | 2.49 | 1.66–3.74 | <0.001 |
| LIPI | |||||||
| 0 vs. 1‐2 | 7.6 vs 5.8 | 1.53 | 1.07–2.20 | 0.020 | 1.23 | 0.83–1.81 | 0.296 |
ECOG, Eastern Cooperative Oncology Group; ED, extensive disease; LD, limited disease; LIPI, lung immune prognostic index; PFS, progression‐free survival.